Los Angeles Capital Management LLC Bluebird Bio, Inc. Transaction History

Los Angeles Capital Management LLC

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 03, 2023	BUY	$2.79 - $5.03 $4,185 - $7,545	1,500 Added 1.57%	97,148 $319,000
Q1 2023 May 04, 2023	SELL	$3.14 - $8.22 $95,989 - $251,285	-30,570 Reduced 24.22%	95,648 $304,000
Q4 2022 Feb 06, 2023	BUY	$5.77 - $8.49 $728,277 - $1.07 Million	126,218 New	126,218 $873,000
Q4 2020 Feb 04, 2021	SELL	$27.5 - $37.92 $1.4 Million - $1.93 Million	-50,974 Closed	0 $0
Q3 2020 Nov 02, 2020	SELL	$34.44 - $43.75 $294,014 - $373,493	-8,537 Reduced 14.35%	50,974 $2.75 Million
Q2 2020 Aug 05, 2020	BUY	$27.12 - $45.97 $1.61 Million - $2.74 Million	59,511 New	59,511 $2.35 Million
Q2 2019 Jul 29, 2019	SELL	$75.84 - $105.21 $2.7 Million - $3.74 Million	-35,585 Closed	0 $0
Q1 2019 Apr 25, 2019	BUY	$64.44 - $104.11 $1.53 Million - $2.48 Million	23,810 Added 202.21%	35,585 $5.6 Million
Q4 2018 Feb 11, 2019	SELL	$59.1 - $93.26 $1.08 Million - $1.71 Million	-18,322 Reduced 60.88%	11,775 $1.17 Million
Q3 2018 Nov 05, 2018	SELL	$88.86 - $117.49 $9.33 Million - $12.3 Million	-104,989 Reduced 77.72%	30,097 $4.39 Million
Q2 2018 Jul 31, 2018	BUY	$99.64 - $127.59 $11.7 Million - $15 Million	117,370 Added 662.51%	135,086 $21.2 Million
Q1 2018 Apr 27, 2018	BUY	$105.8 - $150.94 $778,582 - $1.11 Million	7,359 Added 71.05%	17,716 $3.03 Million
Q4 2017 Feb 05, 2018	BUY	$81.25 - $130.7 $458,168 - $737,017	5,639 Added 119.52%	10,357 $1.85 Million
Q3 2017 Nov 06, 2017	BUY	$57.74 - $91.42 $272,417 - $431,319	4,718	4,718 $648,000

112

61.5M

264K

428K

Ticker BLUE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,121,800
Market Cap $485M
Description
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell ...

Get notified when there are updates to the investment portfolio of Los Angeles Capital Management LLC, based on Form 13F filings with the SEC.

Stay updated on Los Angeles Capital Management LLC with notifications on news.